Global Economic Intersection
Advertisement
  • Home
  • Economics
  • Finance
  • Politics
  • Investments
    • Invest in Amazon $250
  • Cryptocurrency
    • Best Bitcoin Accounts
    • Bitcoin Robot
      • Quantum AI
      • Bitcoin Era
      • Bitcoin Aussie System
      • Bitcoin Profit
      • Bitcoin Code
      • eKrona Cryptocurrency
      • Bitcoin Up
      • Bitcoin Prime
      • Yuan Pay Group
      • Immediate Profit
      • BitQH
      • Bitcoin Loophole
      • Crypto Boom
      • Bitcoin Treasure
      • Bitcoin Lucro
      • Bitcoin System
      • Oil Profit
      • The News Spy
      • Bitcoin Buyer
      • Bitcoin Inform
      • Immediate Edge
      • Bitcoin Evolution
      • Cryptohopper
      • Ethereum Trader
      • BitQL
      • Quantum Code
      • Bitcoin Revolution
      • British Trade Platform
      • British Bitcoin Profit
    • Bitcoin Reddit
    • Celebrities
      • Dr. Chris Brown Bitcoin
      • Teeka Tiwari Bitcoin
      • Russell Brand Bitcoin
      • Holly Willoughby Bitcoin
No Result
View All Result
  • Home
  • Economics
  • Finance
  • Politics
  • Investments
    • Invest in Amazon $250
  • Cryptocurrency
    • Best Bitcoin Accounts
    • Bitcoin Robot
      • Quantum AI
      • Bitcoin Era
      • Bitcoin Aussie System
      • Bitcoin Profit
      • Bitcoin Code
      • eKrona Cryptocurrency
      • Bitcoin Up
      • Bitcoin Prime
      • Yuan Pay Group
      • Immediate Profit
      • BitQH
      • Bitcoin Loophole
      • Crypto Boom
      • Bitcoin Treasure
      • Bitcoin Lucro
      • Bitcoin System
      • Oil Profit
      • The News Spy
      • Bitcoin Buyer
      • Bitcoin Inform
      • Immediate Edge
      • Bitcoin Evolution
      • Cryptohopper
      • Ethereum Trader
      • BitQL
      • Quantum Code
      • Bitcoin Revolution
      • British Trade Platform
      • British Bitcoin Profit
    • Bitcoin Reddit
    • Celebrities
      • Dr. Chris Brown Bitcoin
      • Teeka Tiwari Bitcoin
      • Russell Brand Bitcoin
      • Holly Willoughby Bitcoin
No Result
View All Result
Global Economic Intersection
No Result
View All Result

Key Expert in Supreme Court Lethal Injection Case Did His Research on Drugs.com

admin by admin
April 30, 2015
in Uncategorized
0
0
SHARES
29
VIEWS
Share on FacebookShare on Twitter

Special Report from ProPublica

by Annie Waldman, ProPublica

Tomorrow, when the Supreme Court hears oral arguments in the highest-profile death penalty challenge in seven years, the justices will begin ruling on this question: Does Oklahoma’s use of the common surgical sedative midazolam fail to make prisoners unconscious during lethal injections, thus violating the Eighth Amendment’s protection against “cruel and unusual punishment”? For many court watchers, however, a subject of special scrutiny will be the credibility of Oklahoma’s key expert witness, Dr. Roswell Lee Evans, who has testified that inmates “would not sense the pain” of an execution after receiving a high dose of midazolam.

The case, first brought by four condemned Oklahoma inmates, stems from the botched April 2014 execution of convicted murderer Clayton Lockett. Although Lockett received a substantial dose of midazolam intravenously, it failed to render him unconscious as he was administered the paralytic agent vecuronium bromide and the caustic heart-stopping drug potassium chloride. Witnesses reported that he moaned and writhed on the gurney for more than 40 minutes until his death.

Lethal injections involving midazolam in other states have been similarly grisly. In Ohio, Dennis McGuire heaved and snorted during his 26-minute execution. Last July, Arizona took two hours to execute a man. After these deaths, Evans maintained that midazolam works.

Oklahoma and four other states began using the sedative in 2013 after the American pharmaceutical manufacturer Hospira halted production of the anesthetic sodium thiopental in the wake of increasing anti-death penalty sentiment. Since then, according to the Death Penalty Information Center, midazolam has been used in 15 executions, one-quarter of which were apparently painful.

A number of legal activists and medical professionals have expressed concern that Evans, a board certified psychiatric pharmacist and the dean of the Harrison School of Pharmacy at Auburn University in Alabama, has testified that he has never used midazolam on a patient and has, in fact, never personally induced anesthesia.

According to his curriculum vitae, which he submitted as part of his testimony, the last time Evans published a paper related to his pharmacology research was in 1996. Moreover, his 300-page expert witness report included more than 150 pages of printouts from drugs.com, an online consumer website whose disclaimer reads:

“not intended for medical advice, diagnosis or treatment.”

Last month, 16 professors of pharmacology filed a brief with the Supreme Court that disputes Evans’ testimony.

“It is widely recognized in the scientific and medical community that midazolam alone cannot be used to maintain adequate anesthesia,” the doctors asserted, describing how the drug’s potency does not increase with dosage – a so-called “ceiling effect.” They concluded that midazolam “is incapable of rendering an inmate unconscious prior to the injection of the second and third drugs.”

Dr. Kelly Standifer, one of the brief’s authors and chairwoman of the Department of Pharmaceutical Sciences at the University of Oklahoma College of Pharmacy, told ProPublica that she was “a little horrified” when she read Evans’ testimony.

“My first impression was that it was wrong. These kinds of doses are not given by any clinician. To say that they would know what this dose would do? I don’t think anyone can say that.”

Dr. Richard Weisman, a toxicologist and an associate dean at the University of Miami Miller School of Medicine, said that since midazolam has never been tested on patients at high dosages, it would be impossible for Evans to deduce its efficacy. Weisman said:

“It becomes a big experiment and that’s not good for something like this”

But it’s Evans’ reliance on a consumer website that has attracted the most scrutiny from medical professionals.

“As scientists we use primary literature – it’s a little different than drugs.com,” said Dr. Kathryn Cunningham, the vice chairwoman of the pharmacology and toxicology department at University of Texas Medical Branch and another of the brief’s authors. “As someone who is a scientist, we have resources available to use so we would not go to a website of this sort.”

Even Supreme Court Justice Sonia Sotomayor wrote earlier this year that she was “deeply troubled” by Evans’ research standards. “In contending that midazolam will work as the State intends, Dr. Evans cited no studies, but instead appeared to rely primarily on the Web site www.drugs.com,” Sotomayor noted in a dissenting opinion to stay the execution of Charles F. Warner, one of the original petitioners in the case.

“It is true that we give deference to the district courts. But at some point, we must question their findings of fact, unless we are to abdicate our role of ensuring that no clear error has been committed. We should review such findings with added care when what is at issue is the risk of the needless infliction of severe pain.”

An hour later, Warner was executed after receiving a dose of midazolam. His last words were reportedly, “my body is on fire.”

Evans declined to be interviewed for this article. In his testimony before the federal court in Oklahoma last December, he defended his drugs.com research, describing the website as a

“combination of materials pulled from some of the most outstanding references in the country that have been around for 50-plus years.”

Originally from Georgia, Evans received his Doctor of Pharmacy from the University of Tennessee, Memphis, in 1973. He was a professor at the University of Missouri-Kansas City for nearly 20 years before becoming a dean at Auburn University. He is licensed to practice pharmacy in two states—but is not licensed to practice pharmacy in Alabama, the state he has worked in for over 20 years.

A legal expert at the Death Penalty Clinic at the University of California, Berkeley, Megan McCracken said:

“It is telling that the states have selected an expert who does not use or study the drug in question and who based his opinions on unreliable sources.”

The nation’s judicial system has long emphasized the importance and need for reliable scientific testimony, often referred to as the “Daubert Standard.” Under this precedent, established in 1993, all courts have an obligation to ensure that scientific testimony is based on scientific knowledge.

“If you’re trying to figure out whether it’s cruel or unusual punishment, the inquiry into the chemical component needs to be more robust and thorough,” David Loftis, the managing attorney of the Innocence Project, said in an interview with ProPublica. “Just because he’s a scientist doesn’t mean he knows the properties of the drug.”

The problem, Loftis says, is the speed in which death penalty challenges must often be heard. Dale Baich, an attorney representing the Oklahoma prisoners in the Supreme Court case, said this was exactly the situation with Evans, who testified only a month before Charles Warner’s execution date.

Baich said in an interview:

“Because the Oklahoma case went forward in an expedited manner, Dr. Evans was not fully challenged during the hearing as there was no time to take his deposition and conduct an in-depth investigation of his professional background and credentials.”

Ultimately, though, what the intense battle over Evans’ qualifications reveals are the larger forces at work in the country’s ongoing capital punishment debate. “The choice of using a method of execution that is so dependent on the medical profession and pharmacology has bitten the Departments of Corrections in the back” said Deborah Denno, a death penalty expert and professor of law at Fordham University.

“The Departments of Corrections are pretty desperate to find experts who can support their point of view. States have had a lot of trouble finding experts to come forward, and when they do come forward, they are not qualified.”

In recent years, the medical community has begun to speak out against capital punishment. The American Medical Association, the largest association of medical doctors, discourages its members from participating in executions. In 2010, the American Board of Anesthesiology even went so far as to threaten to rescind board certification of any of its 40,000 members if they chose to participate in an execution.

In recent weeks, both the American Pharmacists Association and the International Academy of Compounding Pharmacists have adopted positions discouraging their members from participating in executions.

A consequence of these shifts is that the pool of expert witnesses willing to defend lethal injection is drying up. Take the case of Dr. Mark Dershwitz, a professor of anesthesiology at the University of Massachusetts Medical School. Since at least the early 2000s, Dershwitz has provided expert testimony in more than 20 states on lethal injection drugs (including midazolam). But in June 2014, Dershwitz terminated his role as a state expert. He declined to be interviewed for this article, telling ProPublica in an email,

“as requested by the American Board of Anesthesiology, I do not discuss lethal injection in any venue.”

That may be why states like Oklahoma are turning to doctors such as Roswell Lee Evans – and why his testimony is likely to come under special scrutiny in the Oklahoma case.

ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for their newsletter.

Previous Post

Weakness Across the Board in First Estimate for Q1 GDP

Next Post

April 2015 ISM Manufacturing Survey Unchanged and Remains in Expansion

Related Posts

Shibarium To Use 70% Of Each Base Transaction Fee To Burn Shiba Inu
Economics

Shibarium To Use 70% Of Each Base Transaction Fee To Burn Shiba Inu

by John Wanguba
March 25, 2023
Is Cardano A Good Investment In 2023?
Econ Intersect News

Is Cardano A Good Investment In 2023?

by John Wanguba
March 25, 2023
Canada's Banking Regulator Reiterates Creditor Hierarchy After Credit Suisse Deal Riled Bondholders
Business

Canada’s Banking Regulator Reiterates Creditor Hierarchy After Credit Suisse Deal Riled Bondholders

by John Wanguba
March 25, 2023
Content Moderators Take Meta To Court Over Alleged 'Union-Busting' In Kenya
Business

Content Moderators Take Meta To Court Over Alleged ‘Union-Busting’ In Kenya

by John Wanguba
March 25, 2023
What Are AT1 Bonds And Why Are Credit Suisse’s Depleted?
Business

What Are AT1 Bonds And Why Are Credit Suisse’s Depleted?

by John Wanguba
March 25, 2023
Next Post

Final April 2015 Michigan Consumer Sentiment - Unchanged from the Preliminary Report

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Browse by Category

  • Business
  • Econ Intersect News
  • Economics
  • Finance
  • Politics
  • Uncategorized

Browse by Tags

adoption altcoins bank banking banks Binance Bitcoin Bitcoin adoption Bitcoin market Bitcoin mining blockchain BTC business China crypto crypto adoption cryptocurrency crypto exchange crypto market crypto regulation decentralized finance DeFi Elon Musk ETH Ethereum Europe FTX inflation investment market analysis Metaverse mining NFT nonfungible tokens oil market price analysis recession regulation Russia stock market technology Tesla the UK the US Twitter

Archives

  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • August 2010
  • August 2009

Categories

  • Business
  • Econ Intersect News
  • Economics
  • Finance
  • Politics
  • Uncategorized
Global Economic Intersection

After nearly 11 years of 24/7/365 operation, Global Economic Intersection co-founders Steven Hansen and John Lounsbury are retiring. The new owner, a global media company in London, is in the process of completing the set-up of Global Economic Intersection files in their system and publishing platform. The official website ownership transfer took place on 24 August.

Categories

  • Business
  • Econ Intersect News
  • Economics
  • Finance
  • Politics
  • Uncategorized

Recent Posts

  • Shibarium To Use 70% Of Each Base Transaction Fee To Burn Shiba Inu
  • Is Cardano A Good Investment In 2023?
  • Canada’s Banking Regulator Reiterates Creditor Hierarchy After Credit Suisse Deal Riled Bondholders

© Copyright 2021 EconIntersect - Economic news, analysis and opinion.

No Result
View All Result
  • Home
  • Contact Us
  • Bitcoin Robot
    • Bitcoin Profit
    • Bitcoin Code
    • Quantum AI
    • eKrona Cryptocurrency
    • Bitcoin Up
    • Bitcoin Prime
    • Yuan Pay Group
    • Immediate Profit
    • BitIQ
    • Bitcoin Loophole
    • Crypto Boom
    • Bitcoin Era
    • Bitcoin Treasure
    • Bitcoin Lucro
    • Bitcoin System
    • Oil Profit
    • The News Spy
    • British Bitcoin Profit
    • Bitcoin Trader
  • Bitcoin Reddit

© Copyright 2021 EconIntersect - Economic news, analysis and opinion.

en English
ar Arabicbg Bulgarianda Danishnl Dutchen Englishfi Finnishfr Frenchde Germanel Greekit Italianja Japaneselv Latvianno Norwegianpl Polishpt Portuguesero Romanianes Spanishsv Swedish